Insider Selling: Axon Enterprise (NASDAQ:AXON) Director Sells $100,302.84 in Stock

Axon Enterprise, Inc (NASDAQ:AXON) Director Erika Nardini sold 198 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $506.58, for a total value of $100,302.84. Following the sale, the director owned 1,946 shares of the company’s stock, valued at approximately $985,804.68. This trade represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Axon Enterprise Trading Down 1.2%

Shares of AXON opened at $496.12 on Friday. Axon Enterprise, Inc has a 52-week low of $396.41 and a 52-week high of $885.91. The stock has a market cap of $39.89 billion, a PE ratio of 326.39, a price-to-earnings-growth ratio of 10.72 and a beta of 1.46. The firm’s fifty day moving average is $519.47 and its two-hundred day moving average is $601.32. The company has a quick ratio of 2.29, a current ratio of 2.53 and a debt-to-equity ratio of 0.53.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.55. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The business had revenue of $796.72 million for the quarter, compared to analysts’ expectations of $755.29 million. During the same period in the previous year, the firm posted $2.08 EPS. The business’s revenue for the quarter was up 38.5% compared to the same quarter last year. Research analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Needham & Company LLC cut their price target on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating on the stock in a research note on Friday, February 20th. Barclays dropped their price objective on shares of Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. Robert W. Baird set a $800.00 target price on shares of Axon Enterprise in a research note on Wednesday, February 25th. Royal Bank Of Canada reduced their target price on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a report on Wednesday, February 25th. Finally, Citigroup reissued a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, February 25th. Sixteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $762.93.

Institutional Trading of Axon Enterprise

Hedge funds and other institutional investors have recently bought and sold shares of the business. Brighton Jones LLC purchased a new position in shares of Axon Enterprise in the 4th quarter valued at about $480,000. NewEdge Advisors LLC lifted its stake in Axon Enterprise by 41.1% during the first quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock worth $1,207,000 after purchasing an additional 668 shares during the last quarter. Empowered Funds LLC lifted its stake in Axon Enterprise by 8.4% during the first quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock worth $1,067,000 after purchasing an additional 157 shares during the last quarter. Woodline Partners LP boosted its holdings in Axon Enterprise by 40.6% in the first quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock valued at $3,646,000 after purchasing an additional 2,003 shares in the last quarter. Finally, Sivia Capital Partners LLC acquired a new position in Axon Enterprise in the second quarter valued at approximately $284,000. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Strong Software & Services momentum supports a higher-margin recurring revenue outlook—analyst write-ups highlight ~38% revenue growth and continued subscription expansion, which underpins long-term upside. Read More.
• Positive Sentiment: Earnings beat: Axon’s Feb. quarter topped estimates on EPS and revenue (revenue up ~38.5% YoY), reinforcing the growth narrative that many investors cite when valuing the stock. Read More.
• Positive Sentiment: Municipal procurement continues to drive hardware + software adoption—local grants (e.g., Decatur, IL) are cited as examples of steady demand for public-safety tech. Read More.
• Positive Sentiment: Institutional/coverage interest (features mentioning funds and “trending” status) can attract flows and boost liquidity, supporting the stock over time. Read More.
• Neutral Sentiment: Aggregator/“trending” articles raise awareness but are not direct fundamental catalysts; useful for retail/institutional interest but don’t change cash flows immediately. Read More.
• Neutral Sentiment: Short-interest data being reported as “0 shares” with NaN changes reads like a reporting error—treat as noise until exchanges/brokers clarify; not an actionable signal now.
• Negative Sentiment: Insider selling: Director Erika Nardini sold 198 shares (~$506.58 avg) and Director Jeri Williams sold 157 shares (~$490 avg) in mid‑March; while small in absolute dollars, these filings can dent sentiment. Read More. Read More.
• Negative Sentiment: Near-term skepticism: critical pieces noting a multi‑day losing streak and a sizable short-term market‑cap decline are amplifying caution and likely contributing to today’s pullback. Read More.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.